Clinical Trial: A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07628582) titled 'A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies' on June 01.

Brief Summary: This is a single-arm, open-label and dose-escalation clinical study to evaluate the LVIVO-TaVec122 product in adult subjects with Relapsed/Refractory B-cell Malignancies.

Study Start Date: Sept. 15, 2026

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory B-cell Malignancies

Intervention: BIOLOGICAL: LVIVO-TaVec122 product

Prior to infusion of the LVIVO-TaVec122 product, subjects will receive bridging therapy if needed.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: The First Affiliated Hospital w...